SYRS, US87184Q2066

Syros Pharmaceuticals stock remains tied to Nasdaq delisting process

Published on 10/31/2026 at 00:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syros Pharmaceuticals stock remains tied to the company's voluntary Nasdaq delisting process. Webull says the firm is no longer engaged in business activities.

Syros faces a wind-down phase

Syros Pharmaceuticals is actively pursuing a voluntary Nasdaq delisting, according to Webull.
The company's gene-expression platform and cancer drug programs remain part of its historical operating profile.

SYRS, US87184Q2066, Illustration mit AI erstellt.

Syros Pharmaceuticals is actively pursuing a voluntary delisting from Nasdaq, while Webull describes the company as no longer engaged in business activities. The company profile on Webull characterizes the move as an ongoing process rather than a return to active commercial operations.

Delisting changes the investor context

The delisting process shifts the focus away from Nasdaq trading and toward the company's wind-down and regulatory status. For investors, that distinction matters because the former operating profile does not by itself indicate a current development program, commercial revenue stream or exchange listing.

Syros's own website still presents its gene-control platform and oncology research history, including tamibarotene research in myelodysplastic syndrome and acute myeloid leukemia. The site also carries an announcement titled Syros Pharmaceuticals Announces Voluntary Delisting from Nasdaq and SEC Deregistration.

What Syros Pharmaceuticals does

Syros Pharmaceuticals is a US biotechnology company headquartered in Cambridge, Massachusetts. Its historical focus was the discovery and development of cancer therapies and medicines that modulate gene expression, with programs including tamibarotene, SY-2101 and SY-5609.

The company profile identifies 68 full-time employees and describes Syros as a specialized developer rather than a diversified pharmaceutical group. It also lists strategic relationships with Incyte and TMRC, linking the business to oncology research and licensing activities.